ArticleInfection and drug resistance2023
Clinical Utility of Contezolid-Containing Regimens in 25 Cases of Linezolid-Intolerable Tuberculosis Patients.
Article in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Evaluation of contezolid's cerebrospinal fluid concentration and safety in tuberculous meningitis patients.Microbiology spectrum · 2026Trial
- Contezolid in tuberculosis therapy: a retrospective analysis of real-world practice in China.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Adverse effects of linezolid in the treatment of drug-resistant tuberculosis: a scoping review.Breathe (Sheffield, England) · 2026Review
- Contezolid in the Treatment of Multidrug-Resistant Tuberculous Meningitis: A Case Report.Clinical case reports · 2026Article
- Towards precision dosing of contezolid: moderate hepatic impairment increases plasma concentration of contezolid in anti-tuberculosis treatment.BMC infectious diseases · 2026Observational
- The Structure, Properties, and Clinical Utility of Contezolid for Antituberculosis: A Narrative Review.Infectious diseases and therapy · 2026Review
- From linezolid to contezolid: a strategy for safe continuation of therapy in complex tuberculosis.Frontiers in microbiology · 2026Article
- Safety and Effectiveness of Contezolid versus Linezolid in Drug-Resistant Tuberculosis: A 12-Month Retrospective Study from China.Infection and drug resistance · 2026Article
- Contezolid in tuberculous meningitis: comparable efficacy and favorable safety.Frontiers in cellular and infection microbiology · 2026Article
- Concentration of contezolid in cerebrospinal fluid and serum in a patient with renal allograft tuberculosis and tuberculous meningoencephalitis.BMC infectious diseases · 2025Article
- Clinical outcomes of contezolid in treating complex tuberculosis: real-world evidence from 11 patients.Journal of thoracic disease · 2025Article
- Comparative In Vitro Drug Susceptibility Study of Five Oxazolidinones AgainstPathogens (Basel, Switzerland) · 2025Article
- Treatment of Tuberculous Meningitis With Contezolid in a Patient With Complex Comorbidities: A Case Report and Literature Review.Case reports in infectious diseases · 2025Article
- LC-MS/MS Method for Simultaneous Quantification of Three Oxazolidinone Antimicrobials in Human Plasma: Application to Therapeutic Drug Monitoring.Drug design, development and therapy · 2025Article
- Safety and Tolerability of Contezolid Versus Linezolid for Short-Term Treatment of Rifampicin-Resistant Pulmonary Tuberculosis: A Randomized Controlled Study.Infection and drug resistance · 2025Article
- Clinical Features and Treatment Differences Among Tuberculous, Brucellosis, and Pyogenic Spondylitis: A Cohort Study.Infection and drug resistance · 2025Article
- New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?Pharmaceutics · 2024Review
- Advances in contezolid: novel oxazolidinone antibacterial in Gram-positive treatment.Infection · 2024Review
- Contezolid for the Treatment of Drug-Resistant Tuberculosis in China: A Clinical Case Series.Infection and drug resistance · 2024Article
- The Therapeutic Effect of Contezolid in Complex Intra-Abdominal Infections.Infection and drug resistance · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Linezolid is increasingly used in the treatment of multidrug-resistant (MDR) Methods: We conducted a retrospective study on 25 TB patients who received both linezolid and contezolid in Beijing Chest Hospital from January 1, 2022, to January 31, 2023. All patients received linezolid-containing anti-TB regimen first and then switched to contezolid-containing regimens due to the intolerable linezolid-related AEs. Results: Most (68%, 17/25) of the patients were diagnosed with RR-TB or MDR-TB. A total of 30 AEs were reported in these patients. About 26.7% (8/30) of the AEs were Grade 3 (severe) in severity. After switching to contezolid-containing anti-TB regimens for at least 1 month, the linezolid-related AEs were resolved or improved in 90% of the cases. Clinical improvement was observed in all patients after treatment with contezolid-containing regimen, with negative results of sputum culture and/or smear for Conclusion: Contezolid can be the first choice instead of linezolid to combine with other anti-TB drugs if necessary. Well-designed clinical trials are required to further confirm the safety and efficacy of contezolid in the treatment of TB patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.